Celsion Corporation (NASDAQ:CLSN) plans to raise around $5 million in a public offering announced today. Each share of common stock is priced at $0.23 and each share of the common stock will be come with a one five-year warrant to buy 07.5 of the common stock share, going at an exercise price of $0.23 each share. The offering will be on up to February 21, 2017. This is however dependent on fulfillment of the company’s closing requirements.
Celsion has appointed Rodman & Renshaw, a subsidiary of H.C. Wainwright & Co., LLC, as the exclusive lead placement agent and appointed Maxim Group LLC as the co-placement agent in connection with the offering.
The company is targeting to raise approximately $4.3 million. This figure excludes proceeds from the exercise of the warrant. The company will use the proceeds raised from this offering to fund development of OPTIMA. OPTIMA is Celsion’s ongoing clinical trial of the ThermoDox® in patients suffering from cancer of the liver as well as OVATION. OPTIMA is Phase 111 of the trial while OVATION is Phase 1 trial of the GEN-1 which is administered to patients with advanced cancer of the ovary. The proceed will also go towards funding general corporate functions such as development activities, research , working capital and capital expenditures.
The company now joins the list of Biotech Stocks that have already been listed previously. Gilead sciences, Biogen and Amgen are some of the best Biotech Stocks already listed.
The stocks will be offered in line with a registration statement on Form S-1 (File No. 333-215321) which was filed with the Securities and Exchange Commission (the “SEC”). The statement was declared effective on February 14, 2017.
The stocks will be offered only through a prospectus. The initial prospectus related to the listing was filed with the Securities and Exchange Commission and the final one will be filled on or around February 15, 2017. Details about the offering including copies of the preliminary prospectus as well as the final one can be accessed on SEC’s website as from H.C. Wainwright & Co., LLC